Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Cytori Therapeutics Inc. (NASDAQ: CYTX) shares declined 5.86 percent to close at $2.89 a share Wednesday. The stock traded between $2.81 and $3.07 on volume 1.03 million shares traded. The company reported revenues were $3.5 million for the fourth quarter of 2013, down from $7.3 million in the year ago quarter. Shares of Cytori Therapeutics are up approximately 12.0 percent year-to-date.
Get more information on Cytori Therapeutics free access to the in-depth equity report at: www.FiveStarEquities.com/CYTX
Noranda Aluminum Holding Corp. (NYSE: NOR) shares declined 10.59 percent to close at $4.39 a share Wednesday. The stock traded between $4.26 and $4.58 on volume of 4.60 million shares traded. The company announced a secondary public offering of 10.0 million shares of its common stock held by Apollo Global Management, LLC. Shares of Noranda Aluminum are up approximately 33.0 percent year-to-date.
Get more information on Noranda Aluminum and free access to the in-depth equity report at: www.FiveStarEquities.com/NOR
Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) shares dropped 15.53 percent to close at $12.24 a share Wednesday. The stock traded between $11.88 and $14.64 on volume of 1.09 million shares traded. The company recently announced that it has been granted a 3rd patent in Australia for the oral administration of Exenatide. Shares of Oramed Pharmaceuticals are down approximately 20.0 percent year-to-date.
Get more information on Oramed Pharmaceuticals and free access to the in-depth equity report at: www.FiveStarEquities.com/ORMP
SigmaTron International (NASDAQ: SGMA) shares fell 18.47 percent to close at $8.74 a share Wednesday. The stock traded between $8.11 and $10.50 on volume 275,869 shares traded. The company reported revenues were $54.2 million for the third quarter of fiscal 2014, a decrease of 4.2 percent when compared to the prior quarter. Shares of SigmaTron are down approximately 3.0 percent year-to-date.
Get more information on SigmaTron and free access to the in-depth equity report at: www.FiveStarEquities.com/SGMA
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact: Five Star Equities [email protected]